Leeward Investments LLC MA Lowers Position in Hologic, Inc. (NASDAQ:HOLX)

Leeward Investments LLC MA cut its stake in Hologic, Inc. (NASDAQ:HOLX) by 2.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 138,375 shares of the medical equipment provider’s stock after selling 4,020 shares during the period. Leeward Investments LLC MA owned 0.06% of Hologic worth $9,975,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. State Street Corp lifted its holdings in Hologic by 0.8% in the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock worth $847,944,000 after buying an additional 81,057 shares during the period. FMR LLC lifted its holdings in Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after buying an additional 2,174,093 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Hologic by 0.7% in the third quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock worth $208,051,000 after buying an additional 18,774 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of Hologic by 8.6% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock valued at $200,952,000 after purchasing an additional 195,285 shares during the last quarter. Finally, Nordea Investment Management AB lifted its holdings in shares of Hologic by 32.7% during the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after purchasing an additional 544,889 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.88% of the stock is currently owned by insiders.

Hologic Trading Up 0.2 %

NASDAQ:HOLX opened at $64.47 on Friday. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12 month low of $62.69 and a 12 month high of $84.67. The company has a market cap of $14.47 billion, a PE ratio of 20.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a 50 day simple moving average of $69.91 and a two-hundred day simple moving average of $76.57.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on HOLX shares. Royal Bank of Canada lowered their target price on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a report on Thursday, February 6th. Jefferies Financial Group started coverage on shares of Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 target price for the company. UBS Group lifted their target price on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Raymond James reiterated an “outperform” rating and set a $90.00 target price (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Finally, Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price for the company. in a report on Monday, February 3rd. Ten investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.77.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.